Table 2.
Univariate analysis.
| Variables | Cases | Disease-free survival | P value | |
|---|---|---|---|---|
| (n=107) | Mean ±SD (months) | 5-year (%) | ||
| Age (years) | 0.792 | |||
| ≤40 years | 50 | 92.6±4.4 | 85.1% | |
| >40 years | 57 | 93.5±3.6 | 90.4% | |
| Gender | 0.886 | |||
| Female | 82 | 93.3±3.3 | 89.4% | |
| Male | 25 | 91.2±4.6 | 91.3% | |
| Tumor size | <0.001* | |||
| ≤2.0 cm | 68 | 101.4±2.5 | 96.4% | |
| >2.0 cm | 39 | 74.7±5.3 | 72.3% | |
| TCI | 0.734 | |||
| Negative | 69 | 92.4±3.3 | 86.4% | |
| Positive | 38 | 95.1±4.9 | 91.9% | |
| ETE | 0.049* | |||
| Negative | 55 | 100.0±3.4 | 95.5% | |
| Positive | 52 | 81.2±4.3 | 81.4% | |
| LN metastasis | <0.001* | |||
| Negative | 74 | 100.5±2.6 | 96.3% | |
| Positive | 33 | 78.4±6.5 | 70.4% | |
| TNM stage | <0.001* | |||
| I–II | 84 | 99.7±2.7 | 94.0% | |
| III–IV | 23 | 74.1±7.4 | 68.3% | |
| SMYD2 expression | 0.001* | |||
| Low | 65 | 100.7±2.8 | 92.9% | |
| High | 42 | 78.8±4.9 | 80.9% | |
*
P<0.05 was considered as statistically significant.
ETE – extrathyroidal extension; LN – lymph node; TCI – thyroid capsular invasion; SMYD2 – SET and MYND domain-containing protein 2.